-
CPI-360
- names:
CPI-360
- CAS号:
1802175-06-9
MDL Number: - MF(分子式): C25H31N3O4 MW(分子量): 437.53
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM001320-5mg | 5mg | 99.14% | ¥ 2160.00 | ¥ 2160.00 | 2-3天 | ¥ 0.00 | ||
| YZM001320-2mg | 2mg | 99.14% | ¥ 1378.00 | ¥ 1378.00 | 2-3天 | ¥ 0.00 |
| 中文别名 | |
| 英文别名 | CPI-360 |
| CAS号 | 1802175-06-9 |
| Inchi | |
| InchiKey | |
| 分子式 Formula | C25H31N3O4 |
| 分子量 Molecular Weight | 437.53 |
| 溶解度Solubility | 生物体外In Vitro:DMSO溶解度≥ 48.9 mg/mL(111.76 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知. |
| 性状 | |
| 储藏条件 Storage conditions | 粉末Powder: -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
| 产品说明 | |
| Introduction | CPI60 is a potent, selective EZH2inhibitor with IC50 of 0.5 nM and 2.5 nM nM for wt EZH2 and Y641N EZH2, respectively. IC50 value: 0.5 nM, 2.5 nM |
| Application1 | |
| Application2 | |
| Application3 |
CPI-360 is a potent, selective EZH2inhibitor with IC50 of 0.5 nM and 2.5 nM nM for wt EZH2 and Y641N EZH2, respectively.
IC50 value: 0.5 nM, 2.5 nM
Target: EZH2
in vitro: CPI-360 functions on the basis of S-adenosyl-Lmethionine
(SAM)-competition, inhibits EZH1 about 100-fold less and shows exquisite selectivity across a large panel of histone lysine and arginine, and DNA methyltransferases. CPI-360 potently reduced global H3K27me3 and H3K27me2 levels in a dosedependent manner. CPI-360 effectively suppressed heavy H3K27me3 incorporation in KARPAS-422 cells without affecting total histone turnover. CPI-360 treatment causes time-dependent transcriptional changes in germinal center B cell-like diffuse large B cell lymphoma.
in vivo: Twice daily, subcutaneous administration of 200 mg/kg of
CPI-360 reduced tumor growth (TGI 44%) of KARPAS-422 xenografts in mice without affecting body weight or causing any overt adverse effects. CPI-360 completely inhibits EZH2 catalytic activity, since we entirely suppress H3K27me3 turnover over time.
【1】.Bradley WD, et al. EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation. Chem Biol. 2014 Nov 20;21(11):1463-1475.
【2】.Bruno NC, et al. Design and Preparation of New Palladium Precatalysts for C-C and C-N Cross-Coupling Reactions. Chem Sci. 2013;4:916-920.
【2】.Bruno NC, et al. Design and Preparation of New Palladium Precatalysts for C-C and C-N Cross-Coupling Reactions. Chem Sci. 2013;4:916-920.
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


